logo

Last Update

This profile was last updated on 12/5/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Rhett Schiffman?

Rhett M. Schiffman

Chief Medical Officer and Executive Vice President Research and Development

Envisia Therapeutics Inc

Direct Phone: (919) ***-****direct phone

Email: r***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Envisia Therapeutics Inc

4301 Emperor Blvd. Suite 200

Durham, North Carolina,27703

United States

Company Description

Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT technology platform to develop therapies for a variety of ocular conditio...more

Background Information

Employment History

Chief Medical Officer

Neurotech LLC


Affiliations

GRFS LLC

Board Member


Glaucoma Research Foundation

Board Member


Education

B.S.

Bioengineering

Columbia University


M.D.

University of Juarez , Mexico


MS


Master's degrees

Clinical Research Design and Statistical Analysis and in Health Services Administration

University of Michigan


Web References(38 Total References)


April | 2015 | Envisia

www.envisiatherapeutics.com [cached]

ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER
Envisia Recruits Top Talent to Help Advance Promising Pipeline RESEARCH TRIANGLE PARK, NC - April 14, 2015 - Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology. Read More...


MANAGEMENT | Envisia

www.envisiatherapeutics.com [cached]

Rhett M. Schiffman, M.D.
Chief Medical Officer & Executive Vice President, Research & Development Dr. Rhett Schiffman is Senior Vice President of Development and Chief Medical Officer at Envisia. Previously, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program through phase 1/2 clinical trials. Prior to Neurotech, he was Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan where he played a key role in the global development and approval of many successful products including Restasis®, Combigan®, Lumigan®, Acuvail®/Acular®. Zymaxid®/Zymar®, as well as Lumigan® and Ganfort® unit dose products. Dr. Schiffman received his B.S. in Bioengineering from Columbia University and his M.D. from the University of Juarez, Mexico. He also received Master's degrees from the University of Michigan in Clinical Research Design and Statistical Analysis and in Health Services Administration. He completed residencies in both Internal Medicine and Ophthalmology at Henry Ford Hospital in Michigan and is Board Certified in both specialties and completed a Uveitis fellowship at the National Eye Institute at the National Institutes of Health. He has served on the Board of Directors of the Glaucoma Research Foundation and is Associate Clinical Professor of Ophthalmology at the University of California at Irvine where he sees patients and teaches residents.


ois.net

Rhett Schiffman, Chief Medical Officer and Executive Vice President, R&D - Envisia Therapeutics


ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER | Envisia

www.envisiatherapeutics.com [cached]

ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER
ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER | Envisia Envisia ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER Envisia Recruits Top Talent to Help Advance Promising Pipeline RESEARCH TRIANGLE PARK, NC - April 14, 2015 - Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology. Read More...


ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER | Envisia

www.envisiatherapeutics.com [cached]

ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER
ENVISIA THERAPEUTICS NAMES DR. RHETT SCHIFFMAN CHIEF MEDICAL OFFICER Envisia Recruits Top Talent to Help Advance Promising Pipeline RESEARCH TRIANGLE PARK, NC - April 14, 2015 - Envisia Therapeutics today announced that it has named Rhett M. Schiffman M.D., M.S., M.H.S.A as Chief Medical Officer and Senior Vice President of Development. Prior to Envisia, Dr. Schiffman was the Chief Medical Officer at Neurotech Pharmaceuticals where he led the company's NT-503 program, a cell-based therapy for wet age-related macular degeneration (AMD), through its phase 1/2 studies. He brings with him more than 20 years of expertise and achievements in ophthalmology. Read More...


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory